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The Experience of Conducting Ethical 
Review during the Ebola Virus Disease 
Epidemic in Liberia
Ethics of Clinical Research
Why  should we do research involving human 
participants (clinical research)?  
 How should it be done ethically?
Promoting responsible 
and useful research 
to  benefit society 
and future patients
Protecting the rights and 
welfare of research 
participants, and 
minimizing exploitation
Clinical research involves experimenting on humans with the goal of generating 
useful knowledge and/or remedy about human health and illnesses.
 Benefit to participants is not the goal/purpose of research (although it does 
occur).
 Participants are the means to developing useful knowledge; and are thus at risk 
of exploitation.
Background: EVD Pandemic in West Africa
 The Zaire Ebola virus disease (EVD) outbreak In West Africa was first recognised on March 22, 
2014 in Guinea. 
 Spread rapidly to Sierra Leone and Liberia; Nigeria, and USA.
 Without effective interventions, the CDC initially estimated there could be 550,000 to 1.4 
million cases of EVD by January 20, 2015.
 Vaccine trials: Liberia’s Ministry of Health (MoH); U.S. Department of Health and Human 
Services (HHS); GlaxoSmithKline (license rights to ChAd3 experimental vaccine); NewLink
(license rights to VSV experimental vaccine), now Merck. 
Landmark Interventions
 Liberia – National Institute Allergy and Infectious Diseases (NIAID)/NIH in 2014.
 Sierra Leone – London School of Hygiene and Tropical Medicine (LSHTM) in 2015.
 Guinea – France National Institute of Health and Medical Research (INSERM) in 2015.
 PREVAC – Liberia, Guinea, Sierra Leone and Mali in 2017.
 Other players: Medicine San Frontiers (MSF),  Clinical RM in 2014
 Over 10,000 EVD Survivors are now enrolled in several observational studies in Liberia, SL 
and Guinea.
Was the EVD Outbreak Ethically compelling 
for clinical trials?
 Motives scientifically and globally paramount.
 International Gov’t and Research Organizations 
- WHO.
 National Governments and Health Ministries.
 Medicine & Health Regulatory Authorities 
(MHRAs).
 Research Ethics Boards (REBs).
 Public/Community
Critical Ethical Issues Grappled
 There were plethora of scientific and ethical debates on critical issues 
on conduction of research during emergencies mounting concerns. 
 The Liberian experience is worth mentioning because the EVD outbreak 
changed the fragile ethics review structure. 
 IRBs were whelmed with clinical trials applications between 2014 to 
2016. 
 Study design were debatable: RCT, Single arm ring, Stepped-Wedge, 
etc.
 DSMB requirement.
 Studies needed accelerated reviews which placed ethics committees in 
edgy position.
 Researchers were in speed to have expedited IRB reviews while some 
used unconventional means to get approvals.
Ethical Concerns
 Safety concerns of therapeutics and vaccines candidates and comprehension of the research 
protocols were daunting. 
 Pre-clinical data prior to review were a challenge. 
 PIs were at times confuse on where to go, i.e., NREB or the Liberian Medicine and Health 
Regulatory Authority as both were required. 
 PIs were always anxious to initiate studies at all cost as they believe that epidemic was a 
window of opportunity.
 Insurance 
 Illiteracy (understanding Vs comprehension)
 Harm versus benefits
 Fairness





Clinical Research Protocols Submissions
 There were seven trials protocols submitted to two ethics boards 
in Liberia during the period (2014 – 2016).
- Clinical trials
- Several observational Studies 
- Several social behavioral studies  
 The University of Liberia Institutional Review (UL-IRB) Board and 
the National Research Ethics Board (NREB). 
 Two of these were submitted to the ULIRB and the rest to the 
NREB. The NREB situated under the Ministry of Health was 
responsible for all clinical trials while the ULIRB was responsible 
for all social, behavior and anthropological studies. 
 However, both entities established a collaboration for their 
members to do joint reviews of all clinical trials protocols.
Public Concerns/Apprehensions and Ethics
 Ebola outbreak: high levels of fear and mistrust.
 Conspiracy theories – White man brought it to Liberia.
 Rumors reflect broader anxieties about medical interventions rooted in 
histories of exploitation and mistrust.
 The Trial were attempts to refill a “World Blood Bank.
 The Presidency, Legislature, Media.
 Community liaison encouragement of debates to confront anxieties rather 
than rejecting them as misinformation
 Was it for Liberia’s good? Or global good? How? Why?
Social Mobilization Communication & Advocacy 
The Ethics Boards were also interested in the local cultural setting of 
protocols.
 Clinical trial and/or Social science 
 Research-driven communication strategy
 Community mobilization and engagement 
 Vulnerable stakeholders: EVD Survivors 
 Flyers
 Rumors tracking and power mapping 
 Media/Press role
Conclusion 
 During the emergency, there were salient ethical issues that 
emerged from ethics review oversight from structure and 
composition.
 The design of trials were tailored towards the safety of the 
affected population in the best interest of Liberia and humanity.
 It was observed that trials can be accelerated through structured 
ethics review process once the requirements are met by 
researchers. 
 The Liberian experience was a learning curve for the ethical 
review in the future involving infectious disease research or 
health emergency involving clinical trials.
 Share learning within the West African region and abroad will be 
enhanced.
Medical staff carry  an eight year-old  suspected Ebola victim into a treatment facility in Monrovia in 2014.
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